Mesothelin also called MSLN is encoded by MSLN, which is a tumor differentiation antigen that is normally present on the mesothelial cells lining the pleura, peritoneum and pericardium. The limited mesothelin expression in normal tissues and high expression in many cancers makes it an attractive candidate for therapy. Mesothelin not only is related to mesothelioma, ovarian cancer, pancreatic cancer and lung cancer but also is associated with squamous cell carcinomas such as cervix, lung and head and neck carcinomas and adenocarcinomas.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy product with the complete TCR complex without HLA matching dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE